Ruicheng Yang

Discovery of benzo[d]oxazol-2(3H)-one derivatives as a new class of TNIK inhibitors for the treatment of colorectal cancer.

Linli Li, Shengyong Yang, Xin Luo, 2022, Bioorganic & medicinal chemistry letters.

Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor

Jun Zou, Yifei Wang, Xin Yang, 2022, Nature Communications.

Discovery of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one derivatives as a new class of ROCK inhibitors for the treatment of glaucoma.

Linli Li, Z. Miao, Y. Zhang, 2021, Bioorganic & medicinal chemistry letters.

Discovery of 3,4-Dihydrobenzo[f][1,4]oxazepin-5(2H)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects.

Sheng-yong Yang, Chenyu Tian, Linli Li, 2022, Journal of medicinal chemistry.

A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants

Yifei Wang, H. Chu, J. Nan, 2023, Signal Transduction and Targeted Therapy.

From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases.

Yifei Wang, Chenyu Tian, Shengyong Yang, 2023, Journal of medicinal chemistry.